Compare BOOM & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOOM | BDTX |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 171.9M |
| IPO Year | 1995 | 2020 |
| Metric | BOOM | BDTX |
|---|---|---|
| Price | $6.97 | $2.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $8.50 | ★ $9.67 |
| AVG Volume (30 Days) | 91.9K | ★ 544.1K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 89.02 | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $609,840,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.69 | $1.60 |
| 52 Week High | $9.20 | $4.94 |
| Indicator | BOOM | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 50.15 |
| Support Level | $6.62 | $1.96 |
| Resistance Level | $7.29 | $2.28 |
| Average True Range (ATR) | 0.33 | 0.10 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 34.19 | 17.74 |
DMC Global Inc operates a diversified family of technical product and process businesses serving the energy, industrial and infrastructure markets. Its business is organized into three segments: Arcadia, DynaEnergetics, and NobelClad. Arcadia Products supplies architectural building products, including exterior and interior framing systems, windows, urtain walls, storefronts etc to the commercial construction market. NobelClad is involved in the production of explosion-welded clad metal plates for use in the construction of corrosion-resistant industrial processing equipment and specialized transition joints. DynaEnergetics driver, designs manufactures and distributes products utilized by the oil and gas industry principally for the perforation of oil and gas wells.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.